Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
gptkb:SEL-110
pegadricase |
| gptkbp:administeredBy |
gptkb:ImmTOR
|
| gptkbp:clinicalTrialPhase |
gptkb:NCT04513366
Phase 3 |
| gptkbp:combinationTherapy |
pegadricase and SEL-110
|
| gptkbp:developedBy |
gptkb:Selecta_Biosciences
|
| https://www.w3.org/2000/01/rdf-schema#label |
SEL-212
|
| gptkbp:indication |
chronic refractory gout
|
| gptkbp:mechanismOfAction |
immune tolerance induction
uricase enzyme therapy |
| gptkbp:pegadricaseFunction |
recombinant uricase enzyme
|
| gptkbp:reduces |
serum uric acid levels
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:SEL-110Function |
gptkb:ImmTOR_immune_tolerance_platform
|
| gptkbp:sideEffect |
immunogenicity
infusion reactions |
| gptkbp:status |
investigational
|
| gptkbp:target |
uric acid
|
| gptkbp:therapeuticArea |
rheumatology
|
| gptkbp:bfsParent |
gptkb:Selecta_Biosciences
|
| gptkbp:bfsLayer |
5
|